Fig. 1

LINC00667 acts as an oncogene to promote CRC cell proliferation and migration. a The expression of LINC00667 in the human colon epithelium cell line (FHC) and four human CRC cell lines (HT29, SW620, LoVo and HCT116). Results were obtained using qRT-PCR (n = 3 in each group). b The interfering efficiency of shRNAs specific to LINC00667 was tested by qRT-PCR at 48 h after transfection (n = 3 in each group). c The viability of CRC cells transfected with shNC or shLINC00667#2 for 48 h was measured by CCK-8 assay in several different time points (0 h, 24 h, 48 h, 72 h, 96 h). N = 3 in each group. d The proliferation of LINC00667-silenced cells was detected by EdU assay after treated with shRNAs for 48 h. Red: EdU, blue: DAPI. N = 3 in each group. Scale bar = 200 μm. e Caspase-3 activity was assessed by measuring the wavelength at 405 nm. N = 3 in each group. f The levels of apoptosis-related proteins (Bax and Bcl-2) were measured by western blot analysis in HCT116 and LoVo cells after transfected with shNC or shLINC00667#2. N = 3 in each group. g Transwell assay measured the migratory ability of LINC00667-silenced cells. N = 3 in each group. Scale bar = 200 μm. h Tumors derived from HCT116 cells stably transfected with shNC or shLINC00667#2 were shown. Tumor volume was measured every four days. n = 3 in each group. i Tumor weight in two different groups were shown. n = 3 in each group. ^*P < 0.05, ^**P < 0.01 compared to control group